Investment News
- Home
- About Us
- Newsroom
- Investment News
According to Newsis,
Major biotech(bio-engineering) companies from Korea and India will bolster their cooperation to take the lead in global vaccine and medicine supply chain.
The Association of Biotechnology Led Enterprises (ABLE) announced on July 16 that it held an online meeting jointly with Embassy of India in Korea, in which leaders from Korean and Indian bio technology companies decided to strengthen strategic partnership.
From Korea, SK bioscience, LG Chem, Daewoong Pharmaceutical, and Lab Genomics from Korea participated.
Biocon, Syngene International, Stempeutics, Biocon Biologics, Dr. Reddy's Laboratories, Immune Therapeutics, and Wockhardt from India took part.
According to the ABLE, the participants shared their knowledge on vaccine, biologics, cell and gene therapy, medical technology, and genomics under the theme of 'Asia's potential capability to lead supply chain of vaccine and biologics'
Ambassador Sripriya Ranganathan of India to Korea said Korea's bio-engineering companies have been quick to launch technologies in response to the COVID-19, emphasizing that India is also running policies favorable to companies and investors.
The ambassador said the two countries will ramp up strategic cooperation to develop technologies necessary for global healthcare.
Copyrights Newsis. All Rights Reserved.
Reprint or redistribution without permission is prohibited.
ez@newsis.com
Source: Newsis (July 17, 2021)
** This article was translated from Korean.